Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definition
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Carcinoembryonic antigen industry 3600 synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Application trends
2.1.3. Gender trends
2.1.4. End-user trends
2.1.5. Regional trends
Chapter 3. Carcinoembryonic Antigen Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 – 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Rise in cancer prevalence
3.3.1.2. Growing demand for minimally invasive diagnostic procedures
3.3.1.3. Recent technological advancements in carcinoembryonic antigen diagnostics
3.3.1.4. Increasing per capita healthcare expenditure
3.3.2. Industry pitfalls & challenges
3.3.2.1. Inability to detect early stage cancer
3.3.2.2. Lack of awareness regarding the application of carcinoembryonic antigen tests
3.4. Growth potential analysis
3.4.1. By application
3.4.2. By gender
3.4.3. By end-user
3.5. Regulatory landscape
3.5.1. U.S.
3.5.2. Europe
3.6. Global prevalence of top cancers, by region, 2018
3.6.1. North America
3.6.1.1. U.S.
3.6.1.2. Canada
3.6.2. Europe
3.6.2.1. Germany
3.6.2.2. UK
3.6.2.3. France
3.6.2.4. Spain
3.6.2.5. Italy
3.6.2.6. Poland
3.6.2.7. Russia
3.6.2.8. Sweden
3.6.2.9. Switzerland
3.6.2.10. Netherlands
3.6.3. Asia Pacific
3.6.3.1. China
3.6.3.2. Japan
3.6.3.3. India
3.6.3.4. Australia
3.6.3.5. South Korea
3.6.3.6. New Zealand
3.6.3.7. Malaysia
3.6.3.8. Singapore
3.6.3.9. Indonesia
3.6.3.10. Philippines
3.6.4. Latin America
3.6.4.1. Brazil
3.6.4.2. Mexico
3.6.4.3. Argentina
3.6.4.4. Columbia
3.6.4.5. Peru
3.6.5. Middle East and Africa
3.6.5.1. South Africa
3.6.5.2. Saudi Arabia
3.6.5.3. UAE
3.7. Porter’s analysis
3.8. Competitive landscape, 2017
3.8.1. Business overview
3.8.2. Revenue analysis
3.8.3. Product landscape
3.8.4. Strategy dashboard
3.9. PESTEL analysis
Chapter 4. Carcinoembryonic Antigen Market, By Application
4.1. Global carcinoembryonic antigen market share, by application, 2017 & 2024
4.2. Gastrointestinal Cancer
4.2.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.2. Colon Cancer
4.2.2.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.3. Pancreatic Cancer
4.2.3.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.4. Rectal Cancer
4.2.4.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.5. Liver Cancer
4.2.5.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.6. Stomach Cancer
4.2.6.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.7. Esophageal Cancer
4.2.7.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.8. Gallbladder Cancer
4.2.8.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.9. Anal Cancer
4.2.9.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.3. Breast Cancer
4.3.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.4. Lung Cancer
4.4.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.5. Ovarian Cancer
4.5.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.6. Prostate Cancer
4.6.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.7. Thyroid Cancer
4.7.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
Chapter 5. Carcinoembryonic Antigen Market, By Gender
5.1. Global carcinoembryonic antigen market share, by gender, 2017 & 2024
5.2. Male
5.2.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
5.3. Female
5.3.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
Chapter 6. Carcinoembryonic Antigen Market, By End-user
6.1. Global carcinoembryonic antigen market share, by end-user, 2017 & 2024
6.2. Hospitals
6.2.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
6.3. Diagnostic Centers
6.3.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
6.4. Cancer Centers
6.4.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
6.5. Research and Academic Institutes
6.5.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
6.6. Others
6.6.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
Chapter 7. Carcinoembryonic Antigen Market, By Region
7.1. Carcinoembryonic antigen market share, by region, 2017 & 2024
7.2. North America
7.2.1. Market estimates and forecast, by country, 2013 – 2024
7.2.2. Market estimates and forecast, by application, 2013 – 2024
7.2.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.2.3. Market estimates and forecast, by gender, 2013 – 2024
7.2.4. Market estimates and forecast, by end-user, 2013 – 2024
7.2.5. U.S.
7.2.5.1. Market estimates and forecast, by application, 2013 – 2024
7.2.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.2.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.2.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.2.6. Canada
7.2.6.1. Market estimates and forecast, by application, 2013 – 2024
7.2.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.2.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.2.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3. Europe
7.3.1. Market estimates and forecast, by country, 2013 – 2024
7.3.2. Market estimates and forecast, by application, 2013 – 2024
7.3.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.3. Market estimates and forecast, by gender, 2013 – 2024
7.3.4. Market estimates and forecast, by end-user, 2013 – 2024
7.3.5. Germany
7.3.5.1. Market estimates and forecast, by application, 2013 – 2024
7.3.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.6. UK
7.3.6.1. Market estimates and forecast, by application, 2013 – 2024
7.3.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.7. France
7.3.7.1. Market estimates and forecast, by application, 2013 – 2024
7.3.7.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.7.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.7.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.8. Spain
7.3.8.1. Market estimates and forecast, by application, 2013 – 2024
7.3.8.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.8.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.8.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.9. Italy
7.3.9.1. Market estimates and forecast, by application, 2013 – 2024
7.3.9.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.9.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.9.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.10. Poland
7.3.10.1. Market estimates and forecast, by application, 2013 – 2024
7.3.10.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.10.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.10.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.11. Russia
7.3.11.1. Market estimates and forecast, by application, 2013 – 2024
7.3.11.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.11.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.11.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.12. Sweden
7.3.12.1. Market estimates and forecast, by application, 2013 – 2024
7.3.12.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.12.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.12.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.13. Switzerland
7.3.13.1. Market estimates and forecast, by application, 2013 – 2024
7.3.13.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.13.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.13.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.14. Netherlands
7.3.14.1. Market estimates and forecast, by application, 2013 – 2024
7.3.14.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.14.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.14.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4. Asia Pacific
7.4.1. Market estimates and forecast, by country, 2013 – 2024
7.4.2. Market estimates and forecast, by application, 2013 – 2024
7.4.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.3. Market estimates and forecast, by gender, 2013 – 2024
7.4.4. Market estimates and forecast, by end-user, 2013 – 2024
7.4.5. China
7.4.5.1. Market estimates and forecast, by application, 2013 – 2024
7.4.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.6. Japan
7.4.6.1. Market estimates and forecast, by application, 2013 – 2024
7.4.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.7. India
7.4.7.1. Market estimates and forecast, by application, 2013 – 2024
7.4.7.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.7.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.7.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.8. Australia
7.4.8.1. Market estimates and forecast, by application, 2013 – 2024
7.4.8.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.8.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.8.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.9. South Korea
7.4.9.1. Market estimates and forecast, by application, 2013 – 2024
7.4.9.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.9.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.9.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.10. New Zealand
7.4.10.1. Market estimates and forecast, by application, 2013 – 2024
7.4.10.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.10.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.10.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.11. Malaysia
7.4.11.1. Market estimates and forecast, by application, 2013 – 2024
7.4.11.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.11.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.11.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.12. Singapore
7.4.12.1. Market estimates and forecast, by application, 2013 – 2024
7.4.12.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.12.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.12.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.13. Indonesia
7.4.13.1. Market estimates and forecast, by application, 2013 – 2024
7.4.13.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.13.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.13.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.14. Philippines
7.4.14.1. Market estimates and forecast, by application, 2013 – 2024
7.4.14.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.14.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.14.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5. Latin America
7.5.1. Market estimates and forecast, by country, 2013 – 2024
7.5.2. Market estimates and forecast, by application, 2013 – 2024
7.5.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.3. Market estimates and forecast, by gender, 2013 – 2024
7.5.4. Market estimates and forecast, by end-user, 2013 – 2024
7.5.5. Brazil
7.5.5.1. Market estimates and forecast, by application, 2013 – 2024
7.5.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.6. Mexico
7.5.6.1. Market estimates and forecast, by application, 2013 – 2024
7.5.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.7. Argentina
7.5.7.1. Market estimates and forecast, by application, 2013 – 2024
7.5.7.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.7.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.7.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.8. Columbia
7.5.8.1. Market estimates and forecast, by application, 2013 – 2024
7.5.8.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.8.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.8.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.9. Peru
7.5.9.1. Market estimates and forecast, by application, 2013 – 2024
7.5.9.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.9.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.9.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.9.4. Market estimates and forecast, by age group, 2013 – 2024
7.6. Middle East & Africa
7.6.1. Market estimates and forecast, by country, 2013 – 2024
7.6.2. Market estimates and forecast, by application, 2013 – 2024
7.6.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.6.3. Market estimates and forecast, by gender, 2013 – 2024
7.6.4. Market estimates and forecast, by end-user, 2013 – 2024
7.6.5. South Africa
7.6.5.1. Market estimates and forecast, by application, 2013 – 2024
7.6.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.6.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.6.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.6.6. Saudi Arabia
7.6.6.1. Market estimates and forecast, by application, 2013 – 2024
7.6.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.6.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.6.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.6.7. UAE
7.6.7.1. Market estimates and forecast, by application, 2013 – 2024
7.6.7.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.6.7.2. Market estimates and forecast, by gender, 2013 – 2024
7.6.7.3. Market estimates and forecast, by end-user, 2013 – 2024
Chapter 8. Company Profiles
8.1. F. Hoffmann-La Roche Ltd
8.1.1. Business overview
8.1.2. Financial data
8.1.3. Product landscape
8.1.4. Strategic outlook
8.1.5. SWOT analysis
8.2. Quest Diagnostics
8.2.1. Business overview
8.2.2. Financial data
8.2.3. Product landscape
8.2.4. Strategic outlook
8.2.5. SWOT analysis
8.3. GenWay Biotech Inc.
8.3.1. Business overview
8.3.2. Financial data
8.3.3. Product landscape
8.3.4. Strategic outlook
8.3.5. SWOT analysis
8.4. Correlogic Systems, Inc.
8.4.1. Business overview
8.4.2. Financial data
8.4.3. Product landscape
8.4.4. Strategic outlook
8.4.5. SWOT analysis
8.5. Creative Diagnostics
8.5.1. Business overview
8.5.2. Financial data
8.5.3. Product landscape
8.5.4. Strategic outlook
8.5.5. SWOT analysis
8.6. Omega Diagnostics Group PLC
8.6.1. Business overview
8.6.2. Financial data
8.6.3. Product landscape
8.6.4. Strategic outlook
8.6.5. SWOT analysis
8.7. RayBiotech, Inc.
8.7.1. Business overview
8.7.2. Financial data
8.7.3. Product landscape
8.7.4. Strategic outlook
8.7.5. SWOT analysis
8.8. Boster Biological Technology
8.8.1. Business overview
8.8.2. Financial data
8.8.3. Product landscape
8.8.4. Strategic outlook
8.8.5. SWOT analysis
